Skip to main content
. 2009 Oct 1;9:8.

Figure 2.

Figure 2

Serum antibody response against NY-ESO-1 in patient GO. (A) The IgG and IgM responses against recombinant NY-ESO-1 protein at a serum dilution of 1:1,600 were plotted during the course of the disease. The control recombinant protein used was RL-Akt. The clinical course and treatments shown in the box correspond to the time points. (B) Titration of serum obtained at different time points is shown. Sera from 6 healthy donors were included as a control. (C) The IgG subtype was determined using specific secondary mAbs for detection. (D) The peptide regions recognized by the antibody were determined using 30-mer NY-ESO-1 overlapping peptides.